A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2013; you can also visit the original URL.
The file type is application/pdf
.
Rosiglitazone protection against experimentally-induced intestinal ischemia/re-perfusion
2012
Research in Pharmaceutical Biotechnology
Several studies have shown that peroxisome proliferator-activated receptor- (PPAR) agonists protect against ischemia/re-perfusion (I/R) damage in different organs. This study was carried out to assess the possible role of PPAR on intestinal I/R-mediated tissue injury. This was achieved by evaluating the effects of the PPAR agonist rosiglitazone and the PPAR antagonist bisphenol A diglycidyl ether (BADGE) on experimentally-induced intestinal I/R. The possible underlying mechanisms,
doi:10.5897/rpb11.032
fatcat:7wlmbtaggfcg7g3cxywrr4efae